You remind be of someone that posted under the id donknut at Mako. He kept saying the placements were important. I time and time again said he was missing the big picture. It was the technology and a deal for the company. Once again proven right.
I understand the FDA concern and how quickly it get's approved might matter in the short term. But like Mako this will be a takeout with NSPH in my opinion. So looking at extraneous facts will not be what a buyer looks at. It's what can this company do over time for us. I believe here quite a lot. You get the gram negative and enteric approved you see something between $3.50-$4.00 by a willing buyer in the future. And check with many posters. I tend to be on the low side in recent cases. But in this case I believe I'm right on.
Why do I also think I right here that NSPH goes the way of a tuck in and not in the $10.00 area.
When BioCompatibles was bought out I think in 2010 we did the math and thought there was 50-100% appreciation in the future for BSMD. We thought a tuck in would happen for than company and it did within 9 months.
I'm also on record here after the BioFire deal we thought Nanosphere would also get a deal. In my opinion if it does not happen within the next six months all shareholders need to go after Lurie Investments. In our opinion a $3.50 target plus .50 cents given the research sitting on the shelves at the company. This company missed it big time with not doing the equity offering with Grifols or Thermo Fisher. This was a common sense decision vs a deal with Piper at a significant discount to the closing price the night before.